Collaborations in Autoimmune Disease

BRI collaborates with other research organizations, providing available technologies and materials, and conducting clinical trials in a broad range of disease areas. BRI works collaboratively with scientists in pharmaceutical and biotechnology companies and life science research institutions throughout the world on immune mediated and other diseases. We welcome the opportunity to explore potential research collaborations with you on autoimmune diseases and in other research areas. If you are interested in discussing potential collaboration opportunities, please contact us.

Collaboration Opportunities

Immunogenicity Determination of Biologic Drugs

Recombinant protein therapeutics play an increasingly important role in the treatment of human diseases. However, antibody responses to these protein drugs can adversely impact their safety and efficacy. High affinity antibody responses are preceded by CD4+ T cell responses, which control or provoke the undesirable antibody responses. BRI has developed a platform technology that can be utilized to rapidly and systematically identify immunogenic “hot spots” within protein therapeutics, visualize T cell responses against these proteins, and rationally de-immunize their sequences at key amino acid positions.

Research Collaborations Using BRI Biorepositories

BRI actively maintains 11 different biorepositories including one with healthy control samples for comparison purposes. Scientists use biological samples from the repositories to better understand the biomarkers associated with the progression of the diseases and identify targets for new therapies.

Rapid Epitope Identification

The identification of T-cell epitopes is crucial for the development of effective vaccines against infectious agents and tumors, as well as in the design of Ag-specific modes of immunotherapy for autoimmune and immune-mediated diseases. BRI has developed a tetramer-guided epitope mapping (TGEM) approach to rapidly identify T-cell epitopes. The TGEM approach is based on the direct detection of binding of the TCR to the MHC–peptide complex. It has the advantage of reflecting the dominant T-cell specificity in the test sample, enabling it to be used with peripheral blood from patients or immunized research participants.